ArticleMedicine2026
The causal effect of matrix metalloproteinase 9 on interstitial lung disease risk mediated by effector memory double negative T cells: A mediation Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs) have been implicated in the pathogenesis of interstitial lung disease (ILD). However, the causal role of MMPs in ILD pathogenesis remains to be elucidated. This study aimed to investigate the causal effects of circulating MMPs on ILD risk and to evaluate whether immune cell phenotypes mediate this relationship. A comprehensive Mendelian randomization (MR) and mediation analysis was conducted using publicly available data of genome-wide association study (GWAS) summary statistics. Genetic instruments for 6 MMPs (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, and MMP-12) and 731 immune cell traits were selected. Inverse-variance weighted (IVW) was the primary analytical method, supplemented by other MR techniques. Sensitivity analyses included MR-Egger regression, Cochran Q test, and MR-PRESSO to assess pleiotropy and heterogeneity. Mediation analysis was performed to quantify the proportion of the effect mediated by significant immune cells. Genetically predicted MMP-9 levels showed a significant positive causal effect on ILD risk (odds ratio [OR] = 1.034, 95% confidence interval [CI]: 1.006-1.064, P = .018). Among 731 immune cell phenotypes, 8 were identified as causal for ILD, including effector memory double negative T cells (EM DNT; OR = 1.170, P = .001). MMP-9 was further found to increase the abundance of EM DNT (OR = 1.041, 95% CI: 1.009-1.074, P = .012). Mediation analysis indicated that EM DNT mediated 18.5% of the total effect of MMP-9 on ILD. Sensitivity analyses revealed no evidence of horizontal pleiotropy or significant heterogeneity. This study provides genetic evidence supporting a causal role of MMP-9 in the development of ILD, partially mediated through EM DNT. These findings suggest that MMP-9 and EM DNT could be potential therapeutic targets for preventing or treating ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.